MLB’s Rob Manfred attended a PED seminar yesterday and offered some more words about HGH testing in baseball:
Manfred said that the positive test in England “is an important
confirmation of the strength and science involved” in the H.G.H. blood
test and that baseball was working to apply the test on a widespread
An HGH test may or may not be workable and wonderful and all of that — I really don’t know enough about it, or the drug, to say — but I am rather surprised that everyone keeps referring to this rugby player as evidence that people need to get moving on the test.
Why? Because all of the stories that have come out since that test note that the player wasn’t caught merely by testing. Rather, his league had intelligence (i.e. a tip) that he was using HGH, and then went to specifically test him based on that tip. If they didn’t have the tip, they never would have caught the guy in all likelihood, because HGH doesn’t stay in the bloodstream that long. Indeed, the UK anti-doping agency that caught the guy is on record as saying that intelligence, as opposed to testing, is becoming far more important in their battle against HGH. The same sort of intelligence that nabbed Braves’ prospect Jordan Schafer for HGH just last year.
I don’t offer this to slam baseball’s desire to implement HGH testing. As with most things, a combination approach is best. Do some testing if it makes sense. Use intelligence too. It’s all good. It’s just probably worth remembering that there is more to life than just testing, and that, contrary to what so many writers say, the presence or absence of an HGH test doesn’t automatically render baseball’s drug program effective or ineffective.
With the Braves on the cusp of formalizing their one-year deal with Kurt Suzuki, the market for free agent catcher Matt Wieters is dwindling. ESPN’s Jerry Crasnick references an inside source that lists the Angels, Rockies and Reds as potential suitors for the 30-year-old’s services.
Wieters is coming off of an eight-year career with the Orioles. In 2016, he played through his first full year after undergoing Tommy John surgery in 2014 and batted .243/.302/.409 with 17 home runs and a .711 OPS in 464 PA. A return to Baltimore in 2017 isn’t out of the question, Crasnick writes, citing some within the team that would be open to Wieters stepping into a DH role and catching platoon with Wellington Castillo. However, he also points out that the front office appears divided on the veteran catcher, and sees the Orioles as a long shot for the foreseeable future.
The Angels have already been tied to Wieters this offseason, while the Rockies and Reds don’t appear to have made any formal inquiries so far. Both could use a veteran presence behind the dish, as the Rockies are planning to platoon rookie catcher Tom Murphy with 24-year-old Tony Wolters in the spring. The Reds, meanwhile, are banking on a quick recovery for 28-year-old Devin Mesoraco, who missed most of the 2016 season after undergoing shoulder and hip surgery and forced the club to rely almost exclusively on back-up backstop Tucker Barnhart.
The Red Sox are expecting to go to an arbitration hearing with left-handed reliever Fernando Abad, per Pete Abraham of the Boston Globe. Red Sox president Dave Dombrowski said there was a “decent chance” a hearing would be necessary after countering Abad’s $2.7 million request with $2 million.
Abad, 31, pitched just 12 2/3 innings for Boston after the club acquired him from Minnesota at the trade deadline last season. The lefty earned a cumulative 3.66 ERA, 4.2 BB/9 and 7.9 SO/9 for the two teams in 2016. He received $1.25 million in 2016 and will remain under club control (through arbitration) in 2017. A $2.7 million salary would be a hefty increase for the veteran reliever, who has seen a significant decline since he put up a 1.57 ERA for the Athletics in 2014 and who has not amassed more than 0.6 fWAR in any single season to date.
While the Red Sox aren’t close to settling with Abad, Evan Drellich of the Boston Herald reports that they may be closing in on a settlement with left-handed starter Drew Pomeranz. Pomeranz filed at $5.7 million, while the Sox felt more comfortable at $3.6 million. The two are expected to meet somewhere in the middle to avoid an arbitration hearing later this winter.